GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Notes Receivable

LSB (LakeShore Biopharma Co) Notes Receivable : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Notes Receivable?

LakeShore Biopharma Co's Notes Receivable for the quarter that ended in Sep. 2024 was $0.00 Mil.


LakeShore Biopharma Co Notes Receivable Historical Data

The historical data trend for LakeShore Biopharma Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Notes Receivable Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Notes Receivable
- - - -

LakeShore Biopharma Co Quarterly Data
Mar21 Mar22 Jun22 Sep22 Mar23 Jun23 Sep23 Mar24 Sep24
Notes Receivable Get a 7-Day Free Trial Premium Member Only - - - - -

LakeShore Biopharma Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


LakeShore Biopharma Co Notes Receivable Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.